ClinicalTrials.gg
CompletedNCT03043846TICOSPAUpdated Sep 27, 2019

Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)

An observational study in Axial Spondyloarthritis, sponsored by Association de Recherche Clinique en Rhumatologie. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-27.

Sponsored by Association de Recherche Clinique en Rhumatologie · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
163
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.

Enrollment
8th of 10
163 · median 413
Started
2016
with 1 other
Observational
10 of 40
1 open now
Registered
10th of 40
by date
Lead sponsor
2 of 40
Association de Recherche Clinique en Rhumatologie

Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 8th largest by enrollment of the 10 observational ones that give a count, is one of 2 that started in 2016, is one of 10 observational ones, and was the 10th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Axial Spondyloarthritis with a site in France, or all of them as a file.
02

Study summary

This is a not interventional, pragmatic, prospective, randomized (cluster) study to evaluate the potential benefit of a Treat to Target approach in comparison to routine treatment (i.e. usual care) in patients with axial spondyloarthritis.

Read the detailed description

This study is reflecting the usual care either in accordance to the treating rheumatologist (arm: usual care) or in accordance to the international scientific recommendations (arm: T2T)

The tight control means that as soon as a treatment is initiated in a patient, the time permitting to evaluate its potential efficacy/safety has to be determined. In terms of safety, such time frame can be very short based on the occurrence of adverse events. In terms of efficacy it is usually recommended to evaluate an NSAIDs after 2 to 4 weeks of treatment intake and the TNF blockers after 12 to 16 weeks.

The Treat to Target means that there is an a priori decision of the target to reach while initiating a treatment and more importantly an a priori decision to intensify the treatment in case such target is not achieved.

There will be 2 arms in the study (tight control and treat to target arm and usual care arm).

160 patients (80 patients per arm) will be included during one year by 18 centers (10 in France, 4 in Belgium and 4 in Netherlands). Patients will be followed during 1 year.

03

Conditions studied

  • Axial Spondyloarthritis

Keywords

  • Treat to Target approach
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with a diagnosis of predominant axial spondyloarthritis according to the axial ASAS criteria AND the opinion of the treating rheumatologist, and an active disease defined as an (ASDAS ≥ 2.1), and non-optimally treated with NSAIDs.

Eligibility criteria

Inclusion Criteria:

  • Adults (between 18 and 65 years old)
  • With a diagnosis of axial spondyloarthritis according to the axial ASAS criteria AND the opinion of the treating rheumatologist.
  • Active disease defined as an ASDAS ≥ 2.1
  • Predominant axial disease meaning that:

    • Patients with non-spinal rheumatological symptoms and/or extra-rheumatological manifestations requiring at baseline the initiation of a specific treatment will be excluded.
    • Patients with a past history and/or a current well controlled non-spinal rheumatological or extra-rheumatological features will be eligible for the study.
  • Non-optimally treated with NSAIDs (i.e. who have not received at least 2 NSAIDS, daily during at least 2 weeks at full dose, during the last year). Annex II summarizes the list of commonly used NSAIDs and the definition of a "full" use.
  • With available pelvic X-rays, B27 and MRI of the sacro-iliac joints (performed at any time since symptoms onset)
  • With no to the use of a NSAID
  • With no intake of apremilast during the previous 3 months
  • Able to understand the objectives of the study and to fill the questionnaires
  • Written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
163 participants (actual)
Patient registry
No

Groups and cohorts

  • Tight control and Treat to Target arm

    For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.

    Other: Follow-up every 3 months during 1 year (data collection in eCRF) · Other: Follow-up every month to follow the pre-defined strategy

  • Usual care arm

    For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.

    Other: Follow-up every 3 months during 1 year (data collection in eCRF)

Interventions

  • OtherFollow-up every 3 months during 1 year (data collection in eCRF)
  • OtherFollow-up every month to follow the pre-defined strategy
06

What researchers measure

Primary outcomes

  1. To compare the changes in ASASHI-NRS over the one year of follow-up in the 2 groups

    In the original protocol, the main objective was "to compare the percentage of patients with a significant improvement in the ASAS-HI score after a one year follow-up in the 2 groups". However, after further research on the methodology to better assess the treatment effect on a pragmatic cluster-based strategy trial, we propose to change the primary objective for two reasons in order to: * Calculate a "significant improvement" of the ASAS-HI, we would need to be aware of the minimally clinically important difference, and this threshold has not been yet defined for the regular ASAS-HI nor for the ASAS-HI NRS. * Account for the reduced heterogeneity induced by the fact that patients are clustered, a multilevel analysis (e.g. mixed models with two random effects, the subject and the cluster or center) has been proposed as the most appropriate method. Therefore, we have amended the main objective to: "To compare the changes in ASASHI-NRS over the one year of follow-up in the 2 groups".

    Time frame: After a one year follow-up

Secondary outcomes

  1. To compare the percentage of patients reaching an ASDAS major improvement after a one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  2. To compare the percentage of patients reaching an ASDAS clinically important improvement after a one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  3. To compare the percentage of patients reaching a BASDAI 50 after a one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  4. To compare the change in the ASDAS over one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  5. To compare the change in the BASDAI over one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  6. To compare the change in the ASAS-NSAID score over one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  7. To compare the WPAI after a one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  8. To compare the EQ5D after a one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  9. To compare the self-report questionnaire on health resource utilization after a one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  10. To compare the number and type of adverse events occuring over one year follow-up in the 2 groups.

    Time frame: After a one year follow-up

  11. To compare the treatment effect (...) within the T2T depending on the compliance to the T2T treatment.

    Time frame: After a one year follow-up

07

Study locations

18 sites
  • UZ GENT
    Gent, Belgium
  • Jessa Ziekenhuis
    Hasselt, Belgium
  • Reumatologie Medizorg
    Merksem, Belgium
  • AZ Alma
    Sijsele, Belgium
  • Chu Gabriel Montpied
    Clermont-ferrand, France
  • Chu Grenoble
    Grenoble, France
  • Chu Le Mans
    Le Mans, France
  • Hopital Lapeyronnie
    Montpellier, France
  • Ch Mulhouse
    Mulhouse, France
  • Hopital Cochin
    Paris, France
  • Hopital de La Pitie Salpetriere
    Paris, France
  • Hopital Henri Mondor
    Paris, France
  • Chu Rouen
    Rouen, France
  • Chu Toulouse
    Toulouse, France
  • UMCG
    Groningen, Netherlands
  • Zuyderland MC
    Heerlen, Netherlands
  • LUMC
    Leiden, Netherlands
  • Maastricht UMC
    Maastricht, Netherlands
08

References and documents

Publications

  • Molto A, Lopez-Medina C, Van den Bosch FE, Boonen A, Webers C, Dernis E, van Gaalen FA, Soubrier M, Claudepierre P, Baillet A, Starmans-Kool M, Spoorenberg A, Jacques P, Carron P, Joos R, Lenaerts J, Gossec L, Pouplin S, Ruyssen-Witrand A, Sparsa L, van Tubergen A, van der Heijde D, Dougados M. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021 Nov;80(11):1436-1444. doi: 10.1136/annrheumdis-2020-219585. Epub 2021 May 6. PubMed 33958325 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jun 2019, 30 months.

Of 28 observational studies under Axial Spondyloarthritis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2017
First posted
Feb 6, 2017
StartActual
Nov 30, 2016
Primary completionActual
Jun 18, 2019
CompletionActual
Jun 18, 2019
Last update
Sep 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03043846
Lead sponsor
Association de Recherche Clinique en Rhumatologie
Collaborators
RCTs
Responsible party
Sponsor
First posted
Feb 6, 2017
Start date
Nov 30, 2016
Primary completion
Jun 18, 2019
Completion
Jun 18, 2019
Last update
Sep 27, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion